[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584924":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":70,"collaborators":10,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":10,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":10,"enrollmentInfo":81,"targetDuration":84,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":93,"overallStatus":96,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adults with solid tumor malignancies",null,"Participants' biospecimen samples (Tissue, Excess fluid (i.e., ascites, pleural effusions, and Blood) will be obtained during non-study, routine medical visits whenever possible, to minimize participant risk. Blood samples will be collected up to 5 times from consenting participants.",[13,14,15,16],"Procedure: Blood Sample","Procedure: Tissue Sample","Procedure: Excess fluid Sample","Other: Medical Chart Review",[18,25,31,35],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Blood Sample","Obtained at the time of non-study related routine blood draw.",[9],[24],"Blood Specimen",{"type":19,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Tissue Sample","Obtained at the time of non-study related routine biopsy or surgical procedure.",[9],[30],"Tissue Specimen",{"type":19,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Excess fluid Sample","Obtained at the time of non-study related routine biopsy, surgical procedure, paracentesis, or thoracentesis procedure.",[9],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Medical Chart Review","Demographic, clinical, and pathologic information will be extracted from the medical record",[9],[40],"Medical Record Review",[42],{"name":43,"affiliation":5,"role":44},"Varun Monga, MBBS","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":10,"email":50},"Phu Lam","CONTACT","877-827-3222","Phu.Lam@ucsf.edu",[52],{"facility":5,"status":10,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"San Francisco","California","94143","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-122.41942,37.77493,{"lat":62,"lon":61},[65,67,69],{"name":47,"role":48,"phone":10,"phoneExt":10,"email":66},"Phu.Lam@ucsf.edui",{"name":10,"role":48,"phone":49,"phoneExt":10,"email":68},"cancertrials@ucsf.edu",{"name":43,"role":44,"phone":10,"phoneExt":10,"email":10},{"type":71,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100584924","ucsf-biobank-for-hereditary-cancers-and-tumor-associated-mutations-100584924",false,"NCT06895681","UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations","UCSF Biobank for Studying Hereditary Cancers and Tumor-Associated Mutations","Inclusion Criteria:\n\nFor participants undergoing collection of tissue, ascites, and\u002For pleural effusions:\n\n1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.\n2. Individuals 18 years of age or older on the day of signing informed consent.\n3. Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and\u002For Individuals with a family history or personal history of cancer.\n4. Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol):\n\n   1. Surgical resection\n   2. Biopsy (open, incisional, excisional, punch, core needle, and\u002For fine needle aspiration (FNA) are all permitted)\n   3. Paracentesis\n   4. Thoracentesis\n\nFor participants undergoing blood banking:\n\n1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.\n2. Individuals 18 years of age or older on the day of signing informed consent.\n3. Individuals with a family history or personal history of cancer.\n4. Must be planning to undergo a blood draw as part of their routine care (or as a research procedure under a University of California, San Francisco (UCSF) -sponsored investigator-initiated trial (IIT) protocol); or willing to undergo an additional blood draw outside of their routine care.\n\nExclusion Criteria:\n\n1\\. Known history of HIV, Hepatitis B, or Hepatitis C (as documented in the medical record) or other infectious disease that in the judgment of the investigator could pose a risk to research personnel or mice, or negatively impact Patient derived xenografts (PDX) tumor engraftment.","ALL","18 Years",{"count":82,"type":83},50000,"ESTIMATED","10 Years","OBSERVATIONAL","This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.",[88,89,90,91,92],"Solid Tumor","Solid Tumor, Adult","Somatic Mutation","Solid Tumor, Unspecified, Adult","Hereditary Cancer",[94,95],"Germline Mutations","Tumor-Associated Mutations","NOT_YET_RECRUITING","2026-04-28",{"date":99,"type":100},"2026-05-04","ACTUAL",{"date":102,"type":83},"2026-08-31",{"date":104,"type":83},"2035-12-31",{"name":5,"class":6},1]